10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, Inc. (NASDAQ:TXG)'s strong portfolio of intellectual property and the widespread recognition of its products show its commitment to innovation. The company has recently placed a high ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

EST Cathie Wood’s ARK Investment buys 370K shares of 10x Genomics (TXG) todayInvest with Confidence: Follow TipRanks' Top Wall Street ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report).

10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's ...

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at ...